5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Windlas Biotech Ltd.

•
windlasbiotech.comBSE: 543329NSE: WINDLAS
Market Cap₹ 2,370 Cr.
Current Price
High / Low₹ 1,182 / 697
Stock P/E35.7
Book Value₹ 249
Price to Book2.77
Dividend Yield0.55 %
ROCE16.1 %
ROE12.5 %
Face Value₹ 5

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has delivered good profit growth of 33.7% CAGR over last 5 years
  • Company is almost debt free
  • Company has consistently been profitable over the last 5 years
  • Company has delivered good sales growth of 16.2% CAGR over last 5 years
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.52x)

CONS

  • Receivables are growing faster than sales - a possible quality concern
  • Valuation is stretched - P/E of 35.7 is well above its own 5-year median (23.4)
  • Growth is decelerating - 3Y profit CAGR (16.0%) trails the 5Y trend (33.7%)
  • Expensive relative to growth - PEG of 2.2

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1881.1037.31451338.900.852901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9570.5586.86254068.030.31902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4962.7586.55188767.060.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1150.0025.42114712.940.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1383.9533.17111803.570.94785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1945.5096.14105117.740.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1686.0026.1397008.710.241032.0325.229150.3517.4412.7620.54
8.LUPIN2112.0017.4796574.550.851416.9816.018276.8934.2828.8629.59
9.DRREDDY1151.5029.8396113.390.69435.60-69.108099.80-5.2113.7510.63
10.MANKIND2305.8546.6395242.000.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2477.3538.8969916.930.10482.83927.884018.4831.3520.3520.03
12.WINDLAS1148.4035.662369.860.5515.99-1.79238.5017.6616.0610.60
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
141145153162171175187195203210222233238
124128134142149154164170177184194209213
Operating Profit16171920222123252627292425
OPM %11.68%11.84%12.24%12.53%12.85%11.92%12.33%12.63%12.60%12.62%12.84%10.45%10.60%
2333445455454
Interest0000001111111
Depreciation4333466787888
Profit before Tax15161820231820202123242020
Tax %23.94%26.19%23.38%23.78%24.92%26.38%22.82%23.40%21.81%24.03%24.54%24.89%20.68%
Net Profit000001316161618181516
5.375.796.757.268.176.477.497.457.778.438.487.127.58

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
352307329428466513631760904904
313269287373414453553666799799
Operating Profit3939415552607894105105
OPM %11.17%12.53%12.61%12.79%11.25%11.74%12.39%12.38%11.59%11.59%
4542-1971013181818
Interest6531111455
Depreciation1711913121213283131
Profit before Tax20762522465777808787
Tax %43.59%16.15%34.28%28.38%16.41%25.27%24.52%23.53%23.59%23.59%
Net Profit11641616384358616666
EPS6.8037.658.908.7018.5819.7027.9829.1031.49—
Dividend Payout %0.00%0.00%0.00%0.00%20.03%19.64%19.66%19.93%20.01%—

COMPOUNDED SALES GROWTH

10 Years:
—
5 Years:
16%
3 Years:
21%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
33%
3 Years:
16%

STOCK PRICE CAGR

10 Years:
—
5 Years:
24%
3 Years:
45%
1 Year:
14%

RETURN ON EQUITY

10 Years:
—
5 Years:
13%
3 Years:
13%
Last Year:
13%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Jul 16

₹ 1.26

Rs.6.3000 per share(126%)Final Dividend

2025

Jul 21

₹ 1.16

Rs.5.8000 per share(116%)Final Dividend

2024

Sep 17

₹ 1.10

Rs.5.5000 per share(110%)Dividend

2023

Sep 5

₹ 0.80

Rs.4.0000 per share(80%)Final Dividend

2022

Sep 9

₹ 0.70

Rs.3.5000 per share(70%)Dividend

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
66661110101011
117187203193382389435490551
573129326422932
Trade Payables855883406388132178238
251516252636475275
Total Liabilities289298338296489527626760907
8664709691109179223213
Capital Work in Progress115008146356
231221162365107173223268
351949415975628162
000000136167227
Cash & Bank81318311142531162
1277484104153197384678
Total Assets289298338296489527626760907

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
40313818187110968105
Cash from Investing-11-5-14-20-155-14-92-74-92
Cash from Financing-26-6-51130-44-151-13
-275-8-1532-50

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
62.5162.5162.5162.3462.3461.9961.9961.9063.31
1.592.001.551.521.441.110.930.602.04
10.359.5810.2610.8911.2211.4411.4411.809.84
Government0.000.000.000.000.000.000.000.000.00
25.5525.9125.6825.2525.0125.4725.6425.7024.80

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-01
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-01 - Windlas Biotech Limited has informed the Exchange about Schedule of meet

2026-08-14
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-14 - Windlas Biotech Limited has informed the Exchange about earnings call transcript of Q1 FY27

2026-08-11
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-11 - Windlas Biotech Limited has informed the Exchange about Link of Recording

2026-08-10
Press Release

2026-08-10 - Windlas Biotech Limited has informed the Exchange regarding a press release dated August 10, 2026, titled "press release on "Windlas Biotech Limited Reports its Q1 FY27 Financial Results"".

2026-08-10
Investor Presentation

2026-08-10 - Windlas Biotech Limited has informed the Exchange about Investor Presentation

2026-08-10
Outcome of Board Meeting

2026-08-10 - Windlas Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

2026-08-05
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-05 - Windlas Biotech Limited has informed the Exchange about Schedule of meet

2026-08-05
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-05 - Windlas Biotech Limited has informed the Exchange about Schedule of meet

2026-07-24
Shareholders meeting

2026-07-24 - Submission of Combined Voting Results and Scrutinizer s Report under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations ) of the 25th Annual General Meeting held on July 23, 2026

News

Recent coverage and analyst commentary for WINDLAS

Loading news…

🤖

AI Stock Analyst

Windlas Biotech Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login